Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.47 |
| ▸ | GSR | P00390 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954711 | 0.85 | TXNRD1 (0.48) | TXNRD1GSRMAPTMERTKVCAM1 | |
| SCHEMBL937505 | 0.83 | MERTK (0.49) | TXNRD1GSRMAPTMERTKVCAM1 | |
| SCHEMBL29990867 | 0.83 | MERTK (0.49) | TXNRD1GSRMAPTMERTKVCAM1 | |
| SCHEMBL14444932 | 0.80 | TXNRD1 (0.56) | TXNRD1GSRMAPTHTTMAPK1 | |
| SCHEMBL1737668 | 0.79 | TXNRD1 (0.41) | TXNRD1GSRMAPTMERTKHTT | |
| SCHEMBL27931558 | 0.79 | CHRNB2 (0.40) | TXNRD1GSRMAPTMERTKALDH1A1 | |
| SCHEMBL17285711 | 0.78 | PIN1 (0.44) | MAPTVCAM1 | |
| SCHEMBL28460738 | 0.78 | MAPT (0.43) | TXNRD1GSRMAPTMERTKVCAM1 | |
| SCHEMBL16470410 | 0.77 | MAPT (0.44) | TXNRD1GSRMAPTMERTKHTT | |
| SCHEMBL10697671 | 0.76 | MAPT (0.44) | TXNRD1GSRMAPTMERTKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003867-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20110003867-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20110003867-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| EP-2231609-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074594-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003867-A1 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | KCNA7, KCNN3, KCNJ2 | TXNRD1 2346/4885GSR 2303/4885MAPT 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.